CPRX250117C17500
- 2.50
- 0.000.00%
Catalyst Pharmaceuticals Newsroom
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Stephens Initiates Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $35
Catalyst Pharmaceuticals Analyst Ratings
Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35
Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $36
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $29
Catalyst Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $30
Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Citi Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $27
The Latest Analyst Ratings For Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Analyst Ratings
Truist Adjusts Price Target on Catalyst Pharmaceuticals to $30 From $25, Maintains Buy Rating
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings